View Financial HealthVaxart 배당 및 자사주 매입배당 기준 점검 0/6Vaxart 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-48.2%자사주 매입 수익률총 주주 수익률-48.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesVaxart, Inc. to Report Q1, 2026 Results on May 07, 2026May 02Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of DirectorsApr 25Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLCApr 18Vaxart, Inc. Publishes Positive Data for Its Oral Bivalent Norovirus Candidate in Lactating Women and Their InfantsJan 15Vaxart, Inc. to Report Q3, 2025 Results on Nov 13, 2025Nov 07Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Nov 06Vaxart Receives a Letter from the Office of the General Counsel of NasdaqSep 20Richard John Burgess Responds to Vaxart’s Governance AnnouncementsSep 18+ 1 more updateVaxart, Inc. Reports Additional Phase 1 Data Supporting the Potential Efficacy of Its Second-Generation Norovirus Oral Vaccine CandidateSep 12Richard John Burgess Files an Exempt Solicitation Statement with VaxartSep 10Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025Sep 03Richard John Burgess Urges Vaxart’s Shareholders to Vote Against Reverse Stock SplitSep 02Richard John Burgess Oppose Vaxart’s Latest Reverse Stock SplitAug 22Vaxart, Inc. to Report Q2, 2025 Results on Aug 13, 2025Aug 07Vaxart, Inc.(NasdaqCM:VXRT) dropped from S&P Global BMI IndexJul 10+ 1 more updateVaxart, Inc.(NasdaqCM:VXRT) dropped from NASDAQ Composite IndexJul 08Nasdaq Determines to Delist Vaxart Common Stock, Suspends Trading Effective July 08Jul 02Vaxart, Inc. Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJun 11Vaxart, Inc. Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 28Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 TrialMay 15+ 1 more updateVaxart, Inc. to Report Q1, 2025 Results on May 13, 2025May 02+ 1 more updateVaxart, Inc., Annual General Meeting, May 21, 2025Apr 03Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.Mar 22Vaxart, Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025Mar 13Vaxart, Inc. Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine CandidateMar 11Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award AgreementFeb 11Vaxart, Inc. Announces Board and Committee ChangesJan 30Vaxart Highlights Progress of Covid-19, Norovirus and Influenza ProgramsJan 15Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical TrialJan 14Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance UpdateJan 01Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateDec 03Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024Nov 07Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine CandidateOct 01Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical DysplasiaAug 28Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023) Aug 11Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024Aug 02Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital MarketJul 06Independent Director recently bought Mex$250k worth of stock Jun 21High number of new and inexperienced directors Jun 17Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateJun 15+ 1 more updateFirst quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023) May 15Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024May 09High number of new and inexperienced directors May 06Vaxart, Inc., Annual General Meeting, Jun 11, 2024May 01Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024Mar 08Vaxart, Inc. Announces Chief Executive Officer ChangesMar 06+ 1 more updateLess than half of directors are independent Feb 23Less than half of directors are independent Feb 02Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price RequirementJan 20Vaxart, Inc. Announces CEO ChangesJan 17+ 1 more updateVaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.Jan 16Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersDec 21Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating MothersNov 03Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023Oct 27New minor risk - Market cap size Oct 25High number of new and inexperienced directors Oct 13Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine CandidateSep 07Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023Jul 29Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price RequirementJul 27High number of new and inexperienced directors Jul 24Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine CandidateJul 12High number of new and inexperienced directors Jul 07Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic IndexJun 25Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus CandidateJun 07First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022) May 06High number of new and inexperienced directors Apr 24High number of new and inexperienced directors Mar 30High number of new and inexperienced directors Feb 24Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus CandidateFeb 15Director recently bought Mex$294k worth of stock Dec 30High number of new and inexperienced directors Dec 03High number of new and inexperienced directors Jun 29Key Executive recently bought Mex$322k worth of stock Jun 24High number of new and inexperienced directors Jun 14High number of new and inexperienced directors May 27First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2021) May 10No longer forecast to breakeven May 05High number of new and inexperienced directors May 02High number of new and inexperienced directors Mar 08High number of new and inexperienced directors Feb 10Forecast to breakeven in 2024 Jan 02Forecast to breakeven in 2024 Jan 02High number of new and inexperienced directors Dec 30High number of new and inexperienced directors Dec 30High number of new and inexperienced directors Dec 16No longer forecast to breakeven Dec 01High number of new and inexperienced directors Dec 01High number of new and inexperienced directors Dec 01Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.075 loss in 3Q 2020) Nov 07지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 VXRT * 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: VXRT * 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Vaxart 배당 수익률 vs 시장VXRT *의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (VXRT *)n/a시장 하위 25% (MX)0%시장 상위 25% (MX)0%업계 평균 (Biotechs)0%분석가 예측 (VXRT *) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 VXRT * 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 VXRT * 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 VXRT * 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: VXRT * 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YMX 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/03/22 06:44종가2024/12/23 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vaxart, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mayank MamtaniB. Riley Securities, Inc.Roger SongJefferies LLCnull nullOppenheimer & Co. Inc.2명의 분석가 더 보기
Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLCApr 18
Vaxart, Inc. Publishes Positive Data for Its Oral Bivalent Norovirus Candidate in Lactating Women and Their InfantsJan 15
Vaxart, Inc. Reports Additional Phase 1 Data Supporting the Potential Efficacy of Its Second-Generation Norovirus Oral Vaccine CandidateSep 12
Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025Sep 03
Vaxart, Inc. Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJun 11
Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 TrialMay 15+ 1 more update
Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award AgreementFeb 11
Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical TrialJan 14
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateDec 03
Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine CandidateOct 01
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical DysplasiaAug 28
Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital MarketJul 06
Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateJun 15+ 1 more update
Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price RequirementJan 20
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersDec 21
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating MothersNov 03
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine CandidateSep 07
Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price RequirementJul 27
Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine CandidateJul 12
Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus CandidateJun 07
Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus CandidateFeb 15